Adalimumab biosimilar (Enzene Biosciences)

阿达木单抗生物类似药 (Enzene Biosciences)

Report date: 2025/01/06 14:18:21

Base Information

Drug NameAdalimumab biosimilar (Enzene Biosciences)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesEnzene Biosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEnzene Biosciences LtdAlkem Laboratories Ltd
Inactive CompaniesN/A
Active IndicationsSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A